Literature DB >> 26210798

APOA II genotypes frequency and their interaction with saturated fatty acids consumption on lipid profile of patients with type 2 diabetes.

Neda Noorshahi1, Gity Sotoudeh2, Mahmoud Djalali1, Mohamad Reza Eshraghian3, Mohammad Keramatipour4, Marjan Ghane Basiri1, Farideh Doostan5, Fariba Koohdani6.   

Abstract

BACKGROUND & AIM: Several studies have suggested that APOA II-265T/C polymorphism affect lipid profile. The aim of this study was to investigate the effect of -265T/C APOA II polymorphism and saturated fatty acids (SFA) intake interaction on lipid profile in diabetic population who are at risk for lipid disorders.
METHODS: In this cross sectional study, 697 type 2 diabetic patients participated. Food consumption data were collected using validated semi-quantitative FFQ during the last year. Realtime-PCR was used to determine APOA II-265T/C genotypes. The interaction between the genotypes and SFA intake with lipid profile was tested using analysis of covariance (ANCOVA).
RESULTS: According to APOA II-265T/C (rs5082) genotype distribution results, CC genotype with a frequency of 12.9% and TC with that of 47.7% showed the lowest and highest frequency in our population, respectively. CC genotype subjects had significantly lower total cholesterol, triglyceride, Cholesterol/HDL-c ratio and non-HDL cholesterol than T allele carriers (p = 0.009, p = 0.02, p = 0.02 and p = 0.002, respectively). The interaction between genotype and SFA intake contributed to significant higher levels of LDL-c and LDL/HDL in CCs (p = 0.05 and p = 0.01), suggesting vulnerability of these individuals to high intake of SFA in the diet.
CONCLUSION: APOA II polymorphism may influence the saturated fatty acid intake required to prevent dyslipidemia in the type 2 diabetic population.
Copyright © 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Apolipoprotein A II; Diabetes type 2; Lipid profiles; Saturated fatty acids

Mesh:

Substances:

Year:  2015        PMID: 26210798     DOI: 10.1016/j.clnu.2015.06.008

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  6 in total

1.  The effect of weight loss on HDL subfractions and LCAT activity in two genotypes of APOA-II -265T>C polymorphism.

Authors:  Masoumeh Moradi; Maryam Mahmoudi; Ahmad Saedisomeolia; Roxana Zahirihashemi; Fariba Koohdani
Journal:  Nutr J       Date:  2017-05-25       Impact factor: 3.271

Review 2.  Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence.

Authors:  Mohammad M H Abdullah; Itzel Vazquez-Vidal; David J Baer; James D House; Peter J H Jones; Charles Desmarchelier
Journal:  Nutrients       Date:  2021-02-22       Impact factor: 5.717

3.  Interaction between Apo A-II -265T>C polymorphism and dietary total antioxidant capacity on some anthropometric indices and serum lipid profile in patients with type 2 diabetes mellitus.

Authors:  Banafsheh Jafari Azad; Mehdi Yaseri; Elnaz Daneshzad; Fariba Koohdani
Journal:  J Nutr Sci       Date:  2021-02-09

4.  Interaction between CETP polymorphism and dietary insulin index and load in relation to cardiovascular risk factors in diabetic adults.

Authors:  Faezeh Abaj; Masoumeh Rafiee; Fariba Koohdani
Journal:  Sci Rep       Date:  2021-08-05       Impact factor: 4.379

5.  Dietary acid load modifies the effects of ApoA2-265 T > C polymorphism on lipid profile and serum leptin and ghrelin levels among type 2 diabetic patients.

Authors:  Masoumeh Rafiee; Fariba Koohdani; Faezeh Abaj; Zahra Esmaeily; Zeinab Naeini
Journal:  BMC Endocr Disord       Date:  2022-07-26       Impact factor: 3.263

Review 6.  Apolipoprotein A-II, a Player in Multiple Processes and Diseases.

Authors:  Gabriela Florea; Irina Florina Tudorache; Elena Valeria Fuior; Radu Ionita; Madalina Dumitrescu; Ioana Madalina Fenyo; Violeta Georgeta Bivol; Anca Violeta Gafencu
Journal:  Biomedicines       Date:  2022-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.